After Cantor Fitzgerald and Janney Montgomery gave uniQure NV (NASDAQ: QURE) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Debjit Chattopadhyay maintained a Buy rating on uniQure NV today and set a price target of $42. The company’s shares closed yesterday at $31.96.
Chattopadhyay wrote:
“Our $42 price target is based on a 13-year DCF analysis of the Hemophilia B (65% (5% POS). We anticipate Hemophilia B commercial launch during 2021 and model risk-adjusted peak sales of roughly $820M during 2028. We assume a launch price of $772.5K (durability >5 years), and at peak, we estimate about 775 patients in the U.S. and approximately 1,050 patients in the developed markets who would have received uniQure’s gene therapy, which represents an 50% of the overall commercial opportunity.”
According to TipRanks.com, Chattopadhyay is a 1-star analyst with an average return of -0.2% and a 43.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Voyager Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for uniQure NV with a $49.17 average price target, a 53.8% upside from current levels. In a report issued on July 26, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $58 price target.
.
See today’s analyst top recommended stocks >>
Based on uniQure NV’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.59 million. In comparison, last year the company had a GAAP net loss of $21.27 million.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.
